Search

Your search keyword '"Khac E"' showing total 305 results

Search Constraints

Start Over You searched for: Author "Khac E" Remove constraint Author: "Khac E"
305 results on '"Khac E"'

Search Results

3. Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

5. Incidence, Clinical Presentation, and Associated Factors of Microscopic Colitis in Northern France: A Population-Based Study

6. Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn′s Disease: A French Population-Based Study

7. Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study

11. Complete endoscopic healing is associated with lower disability than partial mucosal healing in Crohn's disease: a prospective multicentric study

24. Hépatite alcoolique aiguë sévère

25. Estimated risk reduction of mortality and transplantation with bezafibrate in patients with PBC and inadequate response to UDCA: application of the UK-PBC and Global PBC risk scores to the BEZURSO trial

28. Efficacy and safety of 8 weeks of elbasvir/grazoprevir in HCV GT4-infected treatment-naīve participants

29. Changes in serum bile acid levels associated with bezafibrate add-on therapy in patients with primary biliary cholangitis and inadequate biochemical response to ursodeoxycholic acid: results from the BEZURSO trial (NCT01654731)

31. Prise en charge endoscopique des fistules gastriques après sleeve gastrectomy par prothèses double queue de cochon: Technique BARTOLI

32. A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)

33. Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

36. PS-001 - Estimated risk reduction of mortality and transplantation with bezafibrate in patients with PBC and inadequate response to UDCA: application of the UK-PBC and Global PBC risk scores to the BEZURSO trial

37. GS-006 - Efficacy and safety of 8 weeks of elbasvir/grazoprevir in HCV GT4-infected treatment-naīve participants

38. LP05 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: Interim analysis of a french multicenter compassionate use program

39. G08 : Incidence of hepatocellular carcinoma (HCC) and complications in alcoholic compensated cirrhosis. Preliminary results of a multicenter prospective French and belgian cohort (INCA Cirral)

40. P1288 : Budd chiari syndrome (BCS) in France from a large national cohort

41. Le syndrome hépato-pulmonaire

42. Le syndrome hepatopulmonaire

43. [Hepatopulmonary syndrome]

44. LBO-01 - A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)

45. O83 NON-INVASIVE DIAGNOSIS OF LIVER FIBROSIS BY FIBROSCAN IN PATIENTS WITH ALCOHOLIC LIVER DISEASE: A META-ANALYSIS WITH INDIVIDUAL DATA

46. O69 ALBUMIN INFUSION FOR BACTERIAL INFECTIONS OTHER THAN SPONTANEOUS BACTERIAL PERITONITIS IN CIRRHOTIC PATIENTS: A MULTICENTER RANDOMIZED CONTROLLED STUDY (ALB-CIRINF STUDY)

49. SAT-282 - Daclatasvir plus Sofosbuvir with or without Ribavirin in Patients with HCV Infection and Decompensated Cirrhosis: Interim Analysis of a French Multicentre Compassionate use Programme

50. ALCOHOL LIVER DISEASE

Catalog

Books, media, physical & digital resources